Am J Transplant, Volume 20, Suppl 3 Archives - Page 92 of 223 - ATC Abstracts

2020 American Transplant Congress
Outcomes of Intra-Operative Steroid Induction in Liver Transplant Recipients
A. Poparad-Stezar, A. Jantz, T. Larson, B. Summers, N. Sulejmani
Henry Ford Hospital, Detroit, MI
*Purpose: Evidence supporting the use of antibody induction (AI) immunosuppression (IS) (antithymocyteglobulin (rATG) and basiliximab (BAS)) for acute rejection (AR) prophylaxis in liver transplant is…
2020 American Transplant Congress
Cardiovascular Risk Factors in Patients after Liver Transplantion
M. Adamczak¹, D. Gojowy¹, J. Stompor¹, J. Adamusik¹, G. Smiech¹, H. Karkoszka¹, R. Krol², A. Wiecek¹
¹Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland, ²Department of General, Vascular and Transplant Surgery, Medical University of Silesia, Katowice, Poland
*Purpose: The aim of this study was to estimate the prevalence of selected cardiovascular risk factors in patients after liver transplantation (LTx).*Methods: Medical records from…
2020 American Transplant Congress
The Relationship Between Frailty and Performance Status in Patients with Cirrhosis Awaiting Liver Transplantation
C. Q. Xu¹, F. Yao², Y. Mohamad², R. Wong², D. Kent², S. Seetharaman², Y. Srisengfa², J. C. Lai²
¹Department of Medicine, UCSF, San Francisco, CA, ²Division of Gastroenterology and Hepatology, Department of Medicine, UCSF, San Francisco, CA
*Purpose: Frailty—a multi-dimensional construct that encapsulates physical function, performance status, and nutritional status—has emerged as a critical determinant of mortality in patients with cirrhosis. Currently,…
2020 American Transplant Congress
Treatment of Hepatic Encephalopathy in Cirrhotic Patients: Does Rifaximin Prevent Clostridioides Difficile Infection? A Retrospective Analysis
J. D. Goldman, V. Aleksenko, J. L. Davila, N. A. Muhktar, K. Kowdley
Swedish Medical Center, Seattle, WA
*Purpose: Clostridioides difficile infection (CDI) is a major cause of morbidity and mortality and new prevention strategies in high-risk patients are needed. Rifaximin has been…
2020 American Transplant Congress
Brincidofovir for Adenovirus Disease in Adult Renal Transplant Recipients: A Case Series
F. Zervou¹, I. Zacharioudakis¹, S. A. Mehta², H. J. Neumann²
¹Infectious Diseases, New York University Langone, New York, NY, ²New York University Langone Transplant Institute, New York, NY
*Purpose: Adenovirus infection can lead to disease in solid organ transplant recipients, including disease of the allograft. Treatment options for severe disease are limited. Brincidofovir…
2020 American Transplant Congress
Evaluation of Optimization of Workflow for Timing of Inpatient Therapeutic Drug Monitoring of Maintenance Immunosuppressive Drugs in Abdominal Transplant Recipients
J. Schulte, S. Mehta, E. Vargas, K. Cunningham
Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL
*Purpose: Therapeutic drug monitoring (TDM) is essential to the safety and efficacy of immunosuppressants (IS) given their narrow therapeutic index. After an internal review, it…
2020 American Transplant Congress
Barriers for Kidney Transplant Evaluation among People Living with HIV and End-Stage Renal Disease in Mississippi
L. A. Shimose¹, M. X. Bueno Rios¹, J. Clark¹, A. Torres², D. Garcia-Anton², W. Cheungpasitporn², P. Vaitla², F. Cabeza-Rivera²
¹Infectious Diseases, University of Mississippi Medical Center, Jackson, MS, ²Nephrology, University of Mississippi Medical Center, Jackson, MS
*Purpose: The number of Kidney transplants (KTx) among people living with HIV (PLWH) who develop end-stage renal disease (ESRD) has been increasing in many transplant…
2020 American Transplant Congress
Alcohol Relapse after Liver Transplant for Alcohol-Related Cirrhosis: A Longitudinal Assessment of Risk Factors for Relapse and Long-Term Survival
B. Rice, N. Mehta, J. L. Dodge, J. D. Grab, C. Sherman
University of California San Francisco, San Francisco, CA
*Purpose: Relapse to alcohol after liver transplant (LT) is common but likely underreported in patients with alcohol-related cirrhosis (AC). The aim of this study was…
2020 American Transplant Congress
Risk Epitope Mismatch Does Not Predict Short Term Heart Transplant Outcomes
Y. Moayedi¹, J. McCaughan², E. Henricksen³, B. Mueller⁴, S. Fan⁴, H. J. Ross¹, K. Khush⁵, B. M. Zhang⁶, J. Teuteberg⁵
¹Cardiology, Ted Rogers Centre for Heart Research, University Health Network, University of Toronto, Toronto, ON, Canada, ²HLA Lab, Belfast Trust, Belfast, Ireland, ³Pharmacy, Stanford Healthcare, Stanford, CA, ⁴Computational Program TRCHR, Ted Rogers Centre for Heart Research, University Health Network, University of Toronto, Toronto, ON, Canada, ⁵Cardiology, Stanford University, Stanford, CA, ⁶HLA Lab, Stanford University, Stanford, CA
*Purpose: Heart transplantation (HT) remains the gold standard treatment for end-stage heart failure. Despite significant improvements in short-term outcomes, the median survival after heart transplantation…
2020 American Transplant Congress
Voriconazole Associated Adverse Drug Events and Drug Monitoring in Lung Transplant Recipients
C. Y. Luo¹, R. G. Nador², R. D. Levy², J. Yee², L. Wei², N. Partovi¹
¹Vancouver General Hospital, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada
*Purpose: Voriconazole is the drug of choice for prophylaxis and treatment of Aspergillus infection in lung transplant ( LTx) recipients. Voriconazole has a narrow therapeutic…